Data to be presented from Phase II study of two patients with short bowel syndrome in an ongoing study of apraglutide BASEL, Switzerland, May 17, 2019 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biopharmaceutical…
Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition and the most common form of short-limb dwarfism NEW YORK & BASEL, Switzerland–Pfizer (NYSE: PFE) today…
– Results establish favorable safety profile and show the potential for efficacy with once-weekly dosing of a next generation GLP-2 analog – In head-to-head rat studies, apraglutide displayed a longer…
BASEL, Switzerland, Jan. 30, 2019 – Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, today announced the appointments of Sandip…
BASEL, Switzerland, Jan. 16, 2019 — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, today announced that the U.S. Food…
